. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Expert Rev Pharmacoecon Outcomes Res. 2019 Oct 22;19(6):645–661. doi: 10.1080/14737167.2019.1680288

Table 7.

Cost and cost-effectiveness studies for surveillance imaging in DLBCL treatment.

Study	Location	Intervention of interest	Indication	Comparator therapy	Mean total cost (2019 USD)	ICER (2019 USD)	Conclusion	Comments
Huntington, et al. [160]	USA	Routine follow-up including biannual CT	DLBCL patients in first remission	Routine follow-up with no imaging	Total per-patient costs: biannual CT, $45,723; no imaging, $42,084	$181,000/QALY	Not cost-effective	Conclusions were robust across one-way and probabilistic sensitivity analyses
Huntington, et al. [160]	USA	Routine follow-up including biannual PET/CT	DLBCL patients in first remission	Routine follow-up with no imaging	Total per-patient costs: biannual PET/CT, $46,778; no imaging, $42,084	$186,000/QALY	Not cost-effective	Conclusions were robust across one-way and probabilistic sensitivity analyses

Abbreviations: CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; ICER, incremental cost-effectiveness ratio; PET, positron-emission tomography; QALY, quality-adjusted life year; USD, US dollars